Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 MV3DfZRwfG:6aXOgRZN{[Xl? M1LXOFExKG6P M4Hvd|czKGh? M3zITWROW09? MXfQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= NV3zT3ViOjR7MEC4O|M>
HT-29 NFywU2dEgXSxdH;4bYMhSXO|YYm= MYexNEBvVQ>? Mn;2O|IhcA>? NGXhbIFFVVOR NVnTfW56WG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 M{\RWlI1QTByOEez
HT-29 MnLFR5l1d3SxeHnjJGF{e2G7 NV;XbWh6OTBibl2= MWG3NkBp MYHEUXNQ MnHBVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> NH3XVHczPDlyMEi3Ny=>
PC3 Mkm4T4lv[XOnIFHzd4F6 MWOxNFAhdk1? NXXYfXBHOSCq MkjGSG1UVw>? NEnTeopRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> NXTk[nI2OjF7N{i2PFM>
PC3 NEPWUpdMcW6jc3WgRZN{[Xl? NWnEfHg1OTByIH7N M3;QVFEhcA>? NYLCUnJLTE2VTx?= M3vCW2Rw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NXXneYh{OjF7N{i2PFM>
PC3 NWnMOlVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXQeHoyNjVizszN NVPEblJnOSCq M3;PemROW09? NYftXndvUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N M2fjRVIyQTd6Nkiz
HEK293 NHe3em1HfW6ldHnvckBCe3OjeR?= NX;SephjOTByIH7N NHzFbGY5KGh? NW\mWWpDTE2VTx?= M3Pyd2lvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= MnvkNlE2Ozl|MEG=
BT-20 NWTpVpFHU2mwYYPlJGF{e2G7 MnL4NlAh|ryP M1XHdWROW09? NEfGc25Fd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= M{KzUlIyOzV|NUWx
U937 MnTqRY51cWKjY4TldolidCCDc4PhfS=> Mk\NOVAh|ryP MXO0PEBp MlfaSG1UVw>? NXXjRW17UW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz M1LYe|IyOTR{MUC2
U937 NFvH[HJCdnSrYnHjeIVzcWGuIFHzd4F6 M{nyXlUxKM7:TR?= MmWzOFghcA>? M{Pre2ROW09? NU\WfGt4TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NIjhNlIzOTF2MkGwOi=>
U937 NV\RNWJWSW62aXLhZ5RmemmjbDDBd5NigQ>? NFP1XmM2OCEQvF2= NX6yWGFnPDhiaB?= NXy3foJoTE2VTx?= NHnCc4ZFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? NY[3S3ZMOjFzNEKxNFY>
MCF-7 MkHLRZV1d3CqYXf5JGF{e2G7 NIXxOYE{OCCwTR?= MmLlOEBp M322OWROW09? NIHHbmRKdmS3Y3XzJIF2fG:yaHHnfS=> NU\1VpBxOjByMkixN|Q>
U87MG MX3LbY5ie2ViQYPzZZk> M3;HV|Eh|ryP Ml\MOkBp NVHLVJE6TE2VTx?= NXjte2k4WG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= NF;6d2gyQTh2OESwOC=>
U87MG M4\5SmtqdmG|ZTDBd5NigQ>? MWexJO69VQ>? NGX2bJE3KGh? MVjEUXNQ MmDlVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= MVSxPVg1QDRyNB?=
U87MG MV\LbY5ie2ViQYPzZZk> MX:xJO69VQ>? NVHicWVZPiCq MWrEUXNQ MljvSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? M1yxbFE6QDR6NEC0
U87MG NY\3RZpuU2mwYYPlJGF{e2G7 MkLzNUDPxE1? M4X6TVYhcA>? M1HDbGROW09? NEDHWXFFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? MmLHNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb M3TN[2F2fG:yaHHnfUBCe3OjeR?= NGTy[2sxNjJizszN M3vJcFI1KGh? NXXOXHFHTE2VTx?= MXrJcoR2[2W|IHH1eI9xcGGpeR?= MV[xPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 NHLwSJJCfXSxcHjh[5khSXO|YYm= MoTiNE4zKM7:TR?= MUGyOEBp NE\mNINFVVOR M{jXRWlv\HWlZYOgZZV1d3CqYXf5 MmrYNVg{QTF7NEm=
H4 M4G4NWZ2dmO2aX;uJGF{e2G7 MXywMlIh|ryP NFT5bZYzPCCq MW\EUXNQ MnKwTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> NEfBWY4yQDB{NEW4OC=>
HeLa NXLtRoY5TnWwY4Tpc44hSXO|YYm= MUexNFAhdk1? NED1[5I{PiCq NInZd45FVVOR MUfJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u MW[xO|U3OzN6NR?=
HeLa M1LZNmZ2dmO2aX;uJGF{e2G7 MmXyNVAxKG6P MUKzOkBp M2PKOGROW09? NWfnWVg5UW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w M2XYR|E4PTZ|M{i1
HeLa MVHGeY5kfGmxbjDBd5NigQ>? NIi3dGUyODBibl2= NHfoeo0{PiCq M3LNRWROW09? NW\jZpd6UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NUXQZ2FKOTd3NkOzPFU>
SYF M4ro[WZ2dmO2aX;uJGF{e2G7 MV[xNFAhdk1? MoDuNlQhcA>? MXXEUXNQ NX7pRWhkUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MoC0NVc2PjN|OEW=
SYF MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPZNVAxKG6P NIP3V2gzPCCq NIjxdFJFVVOR MlK0TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= MYOxO|U3OzN6NR?=
HEK293T MVnBcpRqfmm{YXygRZN{[Xl? MUWxJI5O MYK0JIQ> M{f1e2ROW09? MYHJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= Ml3zNVc1QDV3MEG=
HEK293T NIDJUGhCdnSrdnnyZYwhSXO|YYm= MXuxJI5O MXe0JIQ> NHK1So1FVVOR MYHJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NGH5NY0yPzR6NUWwNS=>
PBMC M3PoUmZ2dmO2aX;uJGF{e2G7 NFm0SlAyKG6P M2DHRVE1KGR? MnnDSG1UVw>? M3nsfnJm\HWlZYOgR2NTPSCmZX7zbZR6 NXTpSnQ6OTd2OEW1NFE>
PBMC NFzTWGtHfW6ldHnvckBCe3OjeR?= M{HqUlEhdk1? MUCxOEBl NV\BV2dvTE2VTx?= NWraVmZjTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? M3HSU|E4PDh3NUCx
HEK293 cells M4PwZ2tqdmG|ZTDBd5NigQ>? MVu1NEBvVQ>? Mme2OFUhdWmw NW[wfXVXTE2VTx?= NE\5cYZKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P NUL4O21ZOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NVr3XXA{TnWwY4Tpc44hSXO|YYm= M17TOFExOCCwTR?= NV;QfpY1PCCq M3POO2ROW09? MW\JcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> MYGxO|EzQDJ4Mh?=
Human mixed lymphocyte NUTvbW17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqyZ3Y2KG6P NGnvemRFVVOR NHHEfXVKSzVyPUGuOkBvVS5? MVGxOlE5PTh4NR?=
Lewis rat lymph node cells M17aSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm1JO69VQ>? NFj6fVlFVVOR NUjDW3RnUUN3ME2yMlYh|ryP M3HaR|E3OTh3OE[1
cells from the thymus of normal BALB/c mice MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;qNVAhdk1? NGrWOZg4OiCq NHLpdGRFVVOR M2XIPGlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= MYSxNFAzOTl2OB?=
MRK-nu-1 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXT[IdKSzVyPUCuPFQ2KHCP M3TqUXNCVkeHUh?=
OCUB-M MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojQTWM2OD13LkK0JJBO MnHJV2FPT0WU
SF539 NVXFcm8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojhTWM2OD1zMT62JJBO MUnTRW5ITVJ?
ES4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrScm1KSzVyPUKxMlUheE1? MljJV2FPT0WU
RL95-2 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\X[YhRUUN3ME2xNFcheE1? M2WyRXNCVkeHUh?=
LC-2-ad Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTR{MzDwUS=> NIP1T3FUSU6JRWK=
Daudi MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;RTWM2OD12M{SgdG0> NU\XdFE6W0GQR1XS
NTERA-S-cl-D1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK4TmhuUUN3ME20OFMheE1? MXfTRW5ITVJ?
OS-RC-2 NX;2NXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\4RpJKSzVyPU[1NkBxVQ>? MW\TRW5ITVJ?
VA-ES-BJ MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTd{MzDwUS=> NGrIZ3ZUSU6JRWK=
GR-ST MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTh2NjDwUS=> NFrCW|hUSU6JRWK=
SW872 NYrlfnZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3TWM2OD16NE[gdG0> MWLTRW5ITVJ?
NOS-1 NHz4d|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPlNYR2UUN3ME24O|EheE1? MULTRW5ITVJ?
MC116 NVL1bJhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O3UmlEPTB;OUi1JJBO MYPTRW5ITVJ?
NCI-H1355 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3Se|h6UUN3ME2xMlAyKG6P NX\MNXZqW0GQR1XS
RPMI-8226 NELDZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLqTWM2OD1zLkG5JI5O MljiV2FPT0WU
TE-15 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu4fmRkUUN3ME2xMlM3KG6P NFPXTFJUSU6JRWK=
Ramos-2G6-4C10 NFL1VmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLQOGlKSzVyPUGuOFYhdk1? NFTNcJJUSU6JRWK=
KU812 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJwMEGgcm0> NV\iSYRFW0GQR1XS
EW-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlyzTWM2OD1{LkG3JI5O M2rVZnNCVkeHUh?=
KS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwNEWgcm0> NYTL[YRUW0GQR1XS
SK-LMS-1 NYDzfHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfuXIdKSzVyPUKuOFkhdk1? M2K3PHNCVkeHUh?=
TGBC1TKB NFXGNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmixTWM2OD1{Lk[5JI5O NYfsdIt6W0GQR1XS
TE-6 NHnoUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv2V2NKSzVyPUKuO|chdk1? MW\TRW5ITVJ?
ETK-1 M2rKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJwOEKgcm0> M2PQbXNCVkeHUh?=
BE-13 NUTx[WNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K2OGlEPTB;Mj65PUBvVQ>? MnH3V2FPT0WU
A3-KAW MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwOUmgcm0> NXfS[2xsW0GQR1XS
TE-10 NX63Ro9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\sN|lCUUN3ME2zMlMhdk1? M{niXHNCVkeHUh?=
DOHH-2 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwM{Wgcm0> MUnTRW5ITVJ?
ES6 NV;ORmY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DNfWlEPTB;Mz60N{BvVQ>? MkP3V2FPT0WU
OPM-2 NYG0dHlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;EWWx7UUN3ME20MlE2KG6P NFnhcZRUSU6JRWK=
SH-4 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT1TWM2OD12LkO0JI5O MVTTRW5ITVJ?
NB13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzUXZByUUN3ME20MlM3KG6P NETiUWJUSU6JRWK=
HUTU-80 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nMSWlEPTB;ND60NkBvVQ>? MX\TRW5ITVJ?
CCRF-CEM MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M334cWlEPTB;ND65OEBvVQ>? NIXMS4FUSU6JRWK=
TGBC24TKB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKzTWM2OD13LkWxJI5O M17kfXNCVkeHUh?=
697 MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILYR2lKSzVyPU[uNlghdk1? NELTSYxUSU6JRWK=
J-RT3-T3-5 Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX1VG5KSzVyPU[uOFYhdk1? MoPtV2FPT0WU
KALS-1 M3H6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTZwNU[gcm0> Mnq2V2FPT0WU
no-10 M3v6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK5XZlHUUN3ME23MlI6KG6P M3fZfHNCVkeHUh?=
SK-NEP-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRThwN{mgcm0> M37xbHNCVkeHUh?=
L-540 NE\ISYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HMO2lEPTB;MUCuOFIhdk1? NYnve2s5W0GQR1XS
JiyoyeP-2003 NFfUT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XSUGlEPTB;MUCuPVQhdk1? MXHTRW5ITVJ?
HH NEjQSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFzLkO5JI5O NX7yRZZIW0GQR1XS
SR MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH1fnlkUUN3ME2xNU41PSCwTR?= MYDTRW5ITVJ?
QIMR-WIL M2Lqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFzLki1JI5O NWH5N4FEW0GQR1XS
A4-Fuk NIXw[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PfWlEPTB;MUOuNVIhdk1? NXG2VVl3W0GQR1XS
CESS NWDONGEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17SbmlEPTB;MUOuNVMhdk1? MkPsV2FPT0WU
KE-37 MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF4LkC3JI5O MkLRV2FPT0WU
SK-UT-1 NI\Ncm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP4Xoh4UUN3ME2xOk45OSCwTR?= M36yUHNCVkeHUh?=
SIG-M5 M2m0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFntXpBKSzVyPUG3MlI2KG6P MXrTRW5ITVJ?
HT NYTYZZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrHNFJKSzVyPUG3MlYhdk1? M2LJXHNCVkeHUh?=
DEL MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnlPI9qUUN3ME2xO{46QSCwTR?= NGj4bpZUSU6JRWK=
SK-PN-DW MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TQcGlEPTB;MkCuNlMhdk1? MVTTRW5ITVJ?
RPMI-8402 NXnvZ|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrFfWxEUUN3ME2yNU44PyCwTR?= M1fnXHNCVkeHUh?=
RPMI-6666 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Lne2lEPTB;MkSuOFIhdk1? MlewV2FPT0WU
NCI-H720 NIrR[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj6TWM2OD1{NT60NUBvVQ>? M4n0fnNCVkeHUh?=
EW-16 NX3wZnZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;uUGlEPTB;Mk[uPFchdk1? NVfCUIMzW0GQR1XS
BL-70 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETRU3RKSzVyPUK4MlM5KG6P MWXTRW5ITVJ?
SF126 M1XXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PyUGlEPTB;M{CuN|ghdk1? M3vPT3NCVkeHUh?=
BC-1 M4DsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTJPVFKSzVyPUOxMlI3KG6P MUTTRW5ITVJ?
MHH-PREB-1 NUfke3d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTN{LkS0JI5O Mn3lV2FPT0WU
A101D Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33M[GlEPTB;M{KuOlIhdk1? MmjHV2FPT0WU
NMC-G1 NFf4eFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\VUYtrUUN3ME2zN{43PyCwTR?= MXvTRW5ITVJ?
LB1047-RCC M{TTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vYRmlEPTB;M{SuOlkhdk1? NGX1O2NUSU6JRWK=
EM-2 M4LlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN6LkWzJI5O M1\5bXNCVkeHUh?=
COLO-684 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHtTWM2OD1|OT64JI5O M{WxN3NCVkeHUh?=
Becker MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfZUo9KSzVyPUSxMlA2KG6P MXnTRW5ITVJ?
BL-41 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrvOXJKSzVyPUSzMlY3KG6P MkG2V2FPT0WU
MDA-MB-134-VI NU\2UJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HjUGlEPTB;NESuNFIhdk1? MVHTRW5ITVJ?
L-363 M3v1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz2c5hKSzVyPUS0Mlc{KG6P NFzVbGdUSU6JRWK=
ECC4 NUn1Nmc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR2Lke4JI5O NUPjc|A4W0GQR1XS
A388 M1znfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ObVJWUUN3ME20OE45OiCwTR?= Mlq4V2FPT0WU
HEL NYHHT|NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR7Lke5JI5O MX;TRW5ITVJ?
RKO NIrwUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi5[GlKSzVyPUWwMlI6KG6P MX;TRW5ITVJ?
KINGS-1 NFnTPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXxdmRKSzVyPUWxMlU2KG6P MmnRV2FPT0WU
EB-3 NE\ncIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTV{Lk[3JI5O NIXabI5USU6JRWK=
ARH-77 NXPtTXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[zS5plUUN3ME21Nk45KG6P NGDWZYxUSU6JRWK=
GCIY NYPPOXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD13Mz60OkBvVQ>? NYTRR2w6W0GQR1XS
NCI-H1304 M3HPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT6TWM2OD13Nz6yNkBvVQ>? MVHTRW5ITVJ?
KARPAS-299 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnrTWM2OD14MT64NkBvVQ>? NH23T2tUSU6JRWK=
IA-LM MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vGdGlEPTB;NkiuNVMhdk1? NUj1SXNkW0GQR1XS
GI-1 NYXVclAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD1OlVtUUN3ME23NE4{QSCwTR?= M4n4NXNCVkeHUh?=
TE-11 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTd5LkG3JI5O NXLPfW5DW0GQR1XS
LS-411N NIj3WFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojtTWM2OD15Nz61O{BvVQ>? MlnuV2FPT0WU
no-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DKW2lEPTB;OEOuNlQhdk1? M1rGOnNCVkeHUh?=
MV-4-11 NEDlO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTh|LkezJI5O NHj6TYVUSU6JRWK=
BV-173 NHywenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zaU2lEPTB;OEOuPVchdk1? M2KxXHNCVkeHUh?=
CMK M{DTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzETWM2OD16ND6xOkBvVQ>? MV\TRW5ITVJ?
LC4-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTh4LkeyJI5O MVrTRW5ITVJ?
COR-L279 NI\PSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fLb2lEPTB;OEeuNlUhdk1? MXrTRW5ITVJ?
NCI-H209 NIjodHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO0TWM2OD16Nz60NUBvVQ>? MmDzV2FPT0WU
Raji NELPOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHrbmVKSzVyPUi5MlczKG6P NG\yTHlUSU6JRWK=
LB996-RCC NIPGOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHzTWM2OD17Mz60N{BvVQ>? NFjWeFBUSU6JRWK=
NCI-H526 NFPpc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m4NmlEPTB;OUOuOVkhdk1? M3jnOnNCVkeHUh?=
KGN NHH2[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfPN|FKSzVyPUm2MlI6KG6P M3;YcnNCVkeHUh?=
MOLT-4 MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PaWmlEPTB;OU[uO|khdk1? MYTTRW5ITVJ?
PF-382 M1L2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X4Z2lEPTB;OU[uO|khdk1? MWXTRW5ITVJ?
BC-3 M1;T[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrxOJpKSzVyPUm5MlE5KG6P Mm[zV2FPT0WU
KARPAS-422 NU\DZ2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXmPGpKSzVyPUGwNk4xQSCwTR?= MULTRW5ITVJ?
SBC-1 NV\kO4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXZfpRKSzVyPUGwO{44PSCwTR?= MXrTRW5ITVJ?
LC-1F M1;i[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL2TWM2OD1zMEiuNFUhdk1? MY\TRW5ITVJ?
GB-1 M4D0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFyOT6wNkBvVQ>? Mlf1V2FPT0WU
SNB75 MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFzOT62PUBvVQ>? M1W4S3NCVkeHUh?=
BB65-RCC NF\k[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrZZYFYUUN3ME2xNVkvQTNibl2= NV\WXoN2W0GQR1XS
NCI-N87 NV7Qd|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLUOlhFUUN3ME2xNlEvQThibl2= MVfTRW5ITVJ?
IST-MEL1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF{Mj6zPEBvVQ>? MWLTRW5ITVJ?
HOP-62 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj4cmlKSzVyPUGyOk45QSCwTR?= MnXGV2FPT0WU
ACN NGLaUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XCbWlEPTB;MUS2Mlc2KG6P NWnsfmg2W0GQR1XS
DMS-114 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjaOVNKSzVyPUG1NE43PyCwTR?= MUHTRW5ITVJ?
MLMA MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjaeXBDUUN3ME2xOVkvQDhibl2= MV7TRW5ITVJ?
HT-144 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljTTWM2OD1zNkWuOFMhdk1? M13xUXNCVkeHUh?=
C2BBe1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqzTWM2OD1zNkeuO|Yhdk1? MUjTRW5ITVJ?
L-428 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF5Nz63JI5O Mn;nV2FPT0WU
DU-4475 NGe3RXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF6Nz62PEBvVQ>? MXXTRW5ITVJ?
CP67-MEL MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\IUWZKSzVyPUG5PU4{QCCwTR?= MXrTRW5ITVJ?
MEG-01 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT2b3pLUUN3ME2yNFEvQTZibl2= M2nSOnNCVkeHUh?=
IST-SL2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nvbGlEPTB;MkC4MlY{KG6P MmjnV2FPT0WU
ES8 M2PyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHTTWM2OD1{MkWuPVQhdk1? MmHHV2FPT0WU
COLO-800 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHGVJBKSzVyPUKzOU4zQCCwTR?= NXz2c3ZZW0GQR1XS
MFH-ino MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;jOGlEPTB;MkO1Mlg1KG6P MkfSV2FPT0WU
OVCAR-4 M1OxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfzTWM2OD1{M{euNlQhdk1? NVXTNZd7W0GQR1XS
PSN1 NGLPOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnhSmtKSzVyPUK0Nk44OSCwTR?= MXTTRW5ITVJ?
EW-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ2Mz6xJI5O NWLvb41jW0GQR1XS
HCC1599 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLsTWM2OD1{NkGuOFchdk1? MnnxV2FPT0WU
SJSA-1 NV\6N2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ5MT60OkBvVQ>? NFXtOVFUSU6JRWK=
ST486 NHi4c3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PDT2lEPTB;Mkm2MlE1KG6P MXPTRW5ITVJ?
NOMO-1 NEDuXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnUSm9KSzVyPUOwNE4zOSCwTR?= MWPTRW5ITVJ?
MN-60 NVyzZoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULpRVdLUUN3ME2zNFUvOzJibl2= MUHTRW5ITVJ?
HCC1187 NWnLdGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfYWGd2UUN3ME2zNFcvOjVibl2= NWG3N4w{W0GQR1XS
SW982 NHnvWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNzND63OUBvVQ>? NVjqdVh2W0GQR1XS
LB647-SCLC M1q1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XhUmlEPTB;M{K4MlcyKG6P M{\rXHNCVkeHUh?=
HC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTN|NT61JI5O M3rafnNCVkeHUh?=
EHEB MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3NTWM2OD1|M{euOVIhdk1? NHr0XWJUSU6JRWK=
TUR M3Plemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN4Mz65OUBvVQ>? NHvYdFBUSU6JRWK=
LU-139 NVG0O2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTQPGxvUUN3ME2zO|gvODJibl2= NELxeIpUSU6JRWK=
NB1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN6ND60OUBvVQ>? MV;TRW5ITVJ?
BB30-HNC NGnZ[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXTTWM2OD1|OEiuN|Ihdk1? M33XW3NCVkeHUh?=
HAL-01 M1HPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN6OT6yOkBvVQ>? MX3TRW5ITVJ?
K5 M{\6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nUR2lEPTB;NEGxMlM4KG6P NGPnPXlUSU6JRWK=
MZ2-MEL M4DGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\lOYl2UUN3ME20NVMvPjRibl2= MWLTRW5ITVJ?
RXF393 NIXQN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TBPWlEPTB;NEG2MlQ2KG6P MYnTRW5ITVJ?
NCI-H1648 NF7NRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTRzNz61N{BvVQ>? M3TROHNCVkeHUh?=
TE-12 NGPUdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTR|ND6yOkBvVQ>? NGPYN5lUSU6JRWK=
EoL-1- MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInLSZNKSzVyPUSzO{46QCCwTR?= NFzWbWRUSU6JRWK=
JAR NHv2b2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR|OD62NkBvVQ>? NEG3XZZUSU6JRWK=
DSH1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD12NUiuPVEhdk1? NF3EUm1USU6JRWK=
NCI-H187 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR4Mj64NUBvVQ>? M2D6RnNCVkeHUh?=
HCE-4 M1rhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR5Nz62OkBvVQ>? MXfTRW5ITVJ?
8-MG-BA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOyXY41UUN3ME21PFEvPTJibl2= NF\WU3NUSU6JRWK=
KLE NH\rVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDBTWM2OD13OEWuNkBvVQ>? M4TE[HNCVkeHUh?=
KNS-42 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXRTWM2OD13OE[uPFEhdk1? MnjxV2FPT0WU
MSTO-211H MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTvTXA4UUN3ME22NFkvPzRibl2= NGPTN4RUSU6JRWK=
GDM-1 M1nMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\ETWM2OD14MUSuNFkhdk1? M1fybnNCVkeHUh?=
TE-1 M2i4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\hTWM2OD14NE[uNVIhdk1? MkLjV2FPT0WU
BT-474 NHfrRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojVTWM2OD14NEeuNFYhdk1? NYDjeJV7W0GQR1XS
KARPAS-45 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILFXXhKSzVyPU[0O{43KG6P NXW2O2FsW0GQR1XS
MOLT-16 NHj1WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInEVGVKSzVyPU[0O{46OyCwTR?= Ml;aV2FPT0WU
KURAMOCHI MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvx[ohKSzVyPU[1O{42OSCwTR?= NH3qVoVUSU6JRWK=
K-562 M4nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\Fe2lEPTB;Nk[5MlUyKG6P NUDhRWNOW0GQR1XS
EKVX MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTZ5Mj63NUBvVQ>? M4HseXNCVkeHUh?=
GAK M3X6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PlOWlEPTB;Nke1MlMhdk1? MWXTRW5ITVJ?
NCI-SNU-5 MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO5T3pKSzVyPU[5NE4xOSCwTR?= MX;TRW5ITVJ?
NCI-H2126 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jR[2lEPTB;N{K2Mlg4KG6P Mlj4V2FPT0WU
CTV-1 NECzU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfwVFdKSzVyPUe0OE46KG6P M1i5NHNCVkeHUh?=
SW962 NXPLZmVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\nTWM2OD15NEiuOFQhdk1? Mk\zV2FPT0WU
MONO-MAC-6 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLjTWM2OD15NU[uPVMhdk1? MWHTRW5ITVJ?
NCI-H748 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTqTHllUUN3ME23OVgvQTlibl2= NXrOZVNTW0GQR1XS
NCI-H524 NHjFb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPQTWM2OD15OECuO|Mhdk1? M{XPUnNCVkeHUh?=
LS-123 NFvSZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF35TXJKSzVyPUe5OU43QSCwTR?= Mo\2V2FPT0WU
NB7 NVW0coRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHsTWM2OD16MUSuNVQhdk1? M4fz[HNCVkeHUh?=
LS-1034 NUDSbHBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m2T2lEPTB;OEK4Mlk5KG6P MWXTRW5ITVJ?
TE-5 NWW2bGc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\GN2VKSzVyPUi4N{42PiCwTR?= NWXWcIlZW0GQR1XS
A704 M{jSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqyR2JFUUN3ME24PVkvOTVibl2= NXrYRnV5W0GQR1XS
TK10 NWDjRpNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvVTWM2OD17MU[uNFMhdk1? MonhV2FPT0WU
NCI-H345 M3XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm5No1KSzVyPUm0N{4zOiCwTR?= NHe1VYdUSU6JRWK=
CGTH-W-1 M17Gd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DyPWlEPTB;OUS4MlE{KG6P NEnRW45USU6JRWK=
NCI-H510A NHjtO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTl6NT6xNkBvVQ>? M1XTW3NCVkeHUh?=
NCI-H1963 NYTV[49XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\rOoRKSzVyPUGuNFMzQTJizszN NIjFeJhUSU6JRWK=
SCC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VSnNKSzVyPUGuNFM1OTRizszN NGrBbJZUSU6JRWK=
EW-11 M2jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrYelE4UUN3ME2xMlA5PzR|IN88US=> NHjVemJUSU6JRWK=
CPC-N MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXiPWNnUUN3ME2xMlA5QCEQvF2= NHK2UoRUSU6JRWK=
NCI-H1417 NXzlSGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHlR4pKSzVyPUGuNVIzPiEQvF2= M4Hnd3NCVkeHUh?=
DG-75 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwMU[yPFUh|ryP NELo[m5USU6JRWK=
HD-MY-Z NWPQRYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIniW5BKSzVyPUGuNVY1OTZizszN MYPTRW5ITVJ?
ATN-1 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\jSXZJUUN3ME2xMlI3OjB7IN88US=> M4flbHNCVkeHUh?=
KM-H2 NXHzT|RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX2TWM2OD1zLkK2OFA5KM7:TR?= MX3TRW5ITVJ?
NCI-H2081 NFXpeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\xPYVZUUN3ME2xMlI3PjN5IN88US=> MoDzV2FPT0WU
HL-60 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\kPI1KSzVyPUGuNlY6PTlizszN MkfVV2FPT0WU
DB NEjuNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;5TGlEPTB;MT6yO|I1OiEQvF2= MYHTRW5ITVJ?
NCI-H1522 M{LnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjnNnRKSzVyPUGuNlg5QDdizszN NYD6fYU2W0GQR1XS
AM-38 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfaTWM2OD1zLkOwO|Ih|ryP M2fYcXNCVkeHUh?=
NCI-H446 M3u0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXScWlKSzVyPUGuN|IyOjFizszN MUjTRW5ITVJ?
SU-DHL-1 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPwTWM2OD1zLkOyPFAyKM7:TR?= M3SwO3NCVkeHUh?=
NH-12 M{PDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\wU2lEPTB;MT6zOlM4PCEQvF2= NXnqdGlqW0GQR1XS
DMS-79 M2PiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnheJNKSzVyPUGuN|Y5PjZizszN NUfDU2lxW0GQR1XS
NCI-H716 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULsc|V2UUN3ME2xMlM5QTh4IN88US=> NWmzV2ZsW0GQR1XS
ML-2 NYizTHRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr6S5A3UUN3ME2xMlQyPTJ7IN88US=> M{OycnNCVkeHUh?=
NB10 M{Da[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwNE[2N|Ih|ryP NVvQNZdPW0GQR1XS
ONS-76 NWT3TJZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\yemlEPTB;MT61N|U3QSEQvF2= M2TK[nNCVkeHUh?=
LOUCY NYXYTGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13wZWlEPTB;MT61OFY2PyEQvF2= NYf6UGVyW0GQR1XS
SCLC-21H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zMbGlEPTB;MT61PFU5OiEQvF2= NF\UTW5USU6JRWK=
TGW MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rQXWlEPTB;MT62N|k4PSEQvF2= Mnz4V2FPT0WU
LXF-289 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LlVGlEPTB;MT63N|I3QCEQvF2= NWf0[Yh{W0GQR1XS
BB49-HNC NUC1NWhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwN{O1PFYh|ryP MkPoV2FPT0WU
NCI-H747 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j6bmlEPTB;MT63OVM1PiEQvF2= MWLTRW5ITVJ?
LU-165 M3\3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfvUYo{UUN3ME2xMlg1QTh4IN88US=> NGfwUJZUSU6JRWK=
OMC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTy[nRKSzVyPUGuPVUxPjZizszN MoXtV2FPT0WU
RCC10RGB NYr0cIZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7JTW4{UUN3ME2xMlk2QDF5IN88US=> M{LRcnNCVkeHUh?=
SW684 NHntZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwOU[wPVkh|ryP MW\TRW5ITVJ?
TE-8 NX;OT45UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f0eGlEPTB;Mj6wOVU2QSEQvF2= MnfhV2FPT0WU
SK-N-DZ NIDBZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4N2lEPTB;Mj6xN|I4PCEQvF2= MkLaV2FPT0WU
EVSA-T M4fOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOw[JVKSzVyPUKuNVc{OTVizszN NF\xOZRUSU6JRWK=
KASUMI-1 M1Hxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;pcpQyUUN3ME2yMlE5QDF3IN88US=> NHy1fG9USU6JRWK=
NKM-1 NHj5NnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K1W2lEPTB;Mj6yOVQ4OiEQvF2= NYHtb4N2W0GQR1XS
CAL-148 NYfsTJZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnkTWM2OD1{LkOzOlE1KM7:TR?= M{\w[nNCVkeHUh?=
NCI-H64 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPpU|hKSzVyPUKuN|QzOzJizszN NGLjcWRUSU6JRWK=
KNS-81-FD Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPZV41rUUN3ME2yMlM3PjJizszN M1nPOnNCVkeHUh?=
KM12 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwNEC4N|kh|ryP M1H4d3NCVkeHUh?=
SW954 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rVeWlEPTB;Mj60O|c4QSEQvF2= M4LS[HNCVkeHUh?=
NCI-H1395 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX6TXJKSzVyPUKuOVI3PDVizszN MljxV2FPT0WU
DJM-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwNkC2N{DPxE1? M12xXnNCVkeHUh?=
COLO-668 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT6TYRKSzVyPUKuPFI3QTVizszN NVqxdYF{W0GQR1XS
NCI-H1436 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHsTWM2OD1{Lki1OlE2KM7:TR?= M4K4VnNCVkeHUh?=
LB2241-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml32TWM2OD1{Lki2PFM6KM7:TR?= M4DXfHNCVkeHUh?=
GT3TKB NWj1Z4oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwOEmwOVUh|ryP Mmf3V2FPT0WU
COLO-824 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLTeFdKSzVyPUKuPFk4PjhizszN MorLV2FPT0WU
ES1 NWLjRlZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny3TWM2OD1{Lki5PFc6KM7:TR?= NXnWOphnW0GQR1XS
LB771-HNC M3v5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m0T2lEPTB;Mj65NFk1PiEQvF2= NIK1UmpUSU6JRWK=
GI-ME-N MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwMEC5NFQh|ryP M33BcHNCVkeHUh?=
NALM-6 NITIdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj1VXpiUUN3ME2zMlAxQTN|IN88US=> M17XTHNCVkeHUh?=
LU-134-A M1[3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTTe|FbUUN3ME2zMlA2PDJ3IN88US=> M4nH[3NCVkeHUh?=
DMS-153 M1;LWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwMEW4NlQh|ryP M1njOHNCVkeHUh?=
MZ1-PC M{XPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfRTWM2OD1|LkC5NFc5KM7:TR?= M2DvWXNCVkeHUh?=
NCI-H1155 NHjqdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX1NFZKSzVyPUOuNVE3OSEQvF2= M2HzN3NCVkeHUh?=
CAS-1 MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\4TINKSzVyPUOuNVM4ODdizszN MYnTRW5ITVJ?
D-502MG NWjKWIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwMUSzPUDPxE1? M2P2OXNCVkeHUh?=
NCI-H2141 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInzV25KSzVyPUOuNVc1PTJizszN M3ryXXNCVkeHUh?=
NB6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\oSIVKSzVyPUOuNVgzPTlizszN NY\kOJJwW0GQR1XS
NCCIT Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNwMkG4NFkh|ryP M2jrU3NCVkeHUh?=
NB69 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\yTlIzUUN3ME2zMlMyQDlzIN88US=> NXHCZZo3W0GQR1XS
JVM-2 M1HBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPFTWM2OD1|LkO2OFM{KM7:TR?= NGX4SFRUSU6JRWK=
K052 M{LScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXHOGdKSzVyPUOuN|c6PjhizszN M1fwTHNCVkeHUh?=
HCC2157 NWfjT5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr6TWM2OD1|LkWzNlI5KM7:TR?= MYXTRW5ITVJ?
KMOE-2 NYHLSZVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNwNUSyOFIh|ryP NXX4NFQ4W0GQR1XS
SF268 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LHRWlEPTB;Mz63NVU2PCEQvF2= MmfpV2FPT0WU
CHP-126 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXrcowxUUN3ME2zMlc3PDV6IN88US=> NVvKZYZzW0GQR1XS
CP66-MEL NUntbpQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLwcJhXUUN3ME2zMlc6ODl2IN88US=> NHLxOlFUSU6JRWK=
NCI-H69 M4nBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPkTWM2OD12LkCxPVM3KM7:TR?= NFvaSmhUSU6JRWK=
A253 NWLiOG81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwMEKxNFEh|ryP MlfEV2FPT0WU
NB14 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPrWFhKSzVyPUSuNVA1PzlizszN M3XOUXNCVkeHUh?=
NCI-H1694 NXfxRY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LVSWlEPTB;ND6xN|EyOiEQvF2= M1js[XNCVkeHUh?=
NCI-H2196 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzwTYJKSzVyPUSuNVcyPjlizszN NWT2NIV3W0GQR1XS
TE-9 NIjUZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwMUe1PFIh|ryP NGHDPZpUSU6JRWK=
D-283MED NXPyTpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PmeGlEPTB;ND6xPFg1KM7:TR?= MW\TRW5ITVJ?
OCI-AML2 NEj2OlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRwMUm0PFkh|ryP MY\TRW5ITVJ?
D-263MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknqTWM2OD12LkKyPVYyKM7:TR?= NV;sbGxKW0GQR1XS
MPP-89 NHm4V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rCXmlEPTB;ND6yO|MxPCEQvF2= NIrLcWVUSU6JRWK=
LAMA-84 NWTQd3lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwM{C0NlEh|ryP M13zZnNCVkeHUh?=
LB373-MEL-D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLiTWM2OD12LkO2O|g6KM7:TR?= NWezbIo5W0GQR1XS
UACC-257 NV\oTWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\xXpRQUUN3ME20MlM6PTN2IN88US=> MVnTRW5ITVJ?
MC-CAR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTRwNEO5PUDPxE1? NFTscXhUSU6JRWK=
COLO-320-HSR Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HyUmlEPTB;ND60OFQzPyEQvF2= Mn;rV2FPT0WU
P30-OHK NH;O[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi1cWVKSzVyPUSuOlY2QDFizszN NEPPT3ZUSU6JRWK=
UACC-812 NGrHN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\LbGlKSzVyPUSuOlkyPjFizszN NYPlPHNmW0GQR1XS
CTB-1 NYrMNpB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DvTmlEPTB;ND63NVU2PSEQvF2= NEnpSotUSU6JRWK=
ALL-PO MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz0bJdKSzVyPUSuPFQxPzdizszN NIrNTXBUSU6JRWK=
SK-MEL-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XSOGlEPTB;ND64Olk2PSEQvF2= NYjoNI1PW0GQR1XS
TC-YIK M{jFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXYTWM2OD12Lkm3PVQzKM7:TR?= NXzhSJRDW0GQR1XS
NCI-H1882 M3TkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTVwMEKwNFEh|ryP M1rSbHNCVkeHUh?=
MHH-CALL-2 NVPrWHJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojETWM2OD13LkC1NFQzKM7:TR?= NUnIR2JzW0GQR1XS
U-87-MG Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwMEm0OlYh|ryP MX3TRW5ITVJ?
NCI-H1092 M{\Rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTmNoxKSzVyPUWuNlY2PTVizszN NIjQeVhUSU6JRWK=
TE-441-T MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrUfHVnUUN3ME21MlI4QDJizszN NV;4cohTW0GQR1XS
SK-MEL-1 NUW0cHFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTVwMkmwOFQh|ryP NH7XdWFUSU6JRWK=
EW-22 NWnJV5V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvMTWM2OD13LkK5OFY3KM7:TR?= MXrTRW5ITVJ?
MZ7-mel NHTBUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjyUZJKSzVyPUWuOFA3QTFizszN NHHBcnJUSU6JRWK=
LP-1 NX7CcXh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLpS|FKSzVyPUWuOFEzQTFizszN NHH4S|NUSU6JRWK=
NCI-SNU-16 M4PWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3CTWM2OD13Lk[0NFc1KM7:TR?= M2jGW3NCVkeHUh?=
LU-65 NEPlcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nLdmlEPTB;NT63OlM4OyEQvF2= MXPTRW5ITVJ?
CW-2 NWPVVVZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXuTWM2OD13Lki1PVU6KM7:TR?= M2jSVXNCVkeHUh?=
WSU-NHL NWHBVVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XSSWlEPTB;NT65OVE4PCEQvF2= MXXTRW5ITVJ?
IST-MES1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LmO2lEPTB;NT65OVQ1OyEQvF2= MUXTRW5ITVJ?
U-266 NIDUeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QUWlEPTB;NT65PFIxOiEQvF2= NUTHeoJGW0GQR1XS
TALL-1 NV3tZZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3JXo5KSzVyPU[uNVQ3QDhizszN MWHTRW5ITVJ?
Calu-6 NEfIb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL3ZnF3UUN3ME22MlE2OzF4IN88US=> MnG0V2FPT0WU
MMAC-SF NUfKbWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf1XVVKSzVyPU[uNVg2PTZizszN M33ORXNCVkeHUh?=
NCI-H82 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTZwMkC0PFkh|ryP NVi4N5lnW0GQR1XS
RS4-11 NWDhZnZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;3eWlEPTB;Nj6yOVg6PyEQvF2= M4\kOnNCVkeHUh?=
SNU-C2B NVqzNXRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZwNEC5Olkh|ryP MX;TRW5ITVJ?
BOKU MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHBR4tVUUN3ME22MlQ4PTl5IN88US=> NXvIUId6W0GQR1XS
C8166 NH\ocYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwNUW5NVIh|ryP NY[yTmNKW0GQR1XS
D-247MG NYrTfXdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Wc2lEPTB;Nz6wOFM1PyEQvF2= MkTTV2FPT0WU
EW-18 M4[3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tv[mlEPTB;Nz6wO|I6OiEQvF2= M{Hx[3NCVkeHUh?=
KG-1 M3TDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\nU4tWUUN3ME23MlYzPzN6IN88US=> NVrMcXljW0GQR1XS
REH MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzwbmRLUUN3ME23MlY5OTB7IN88US=> MUDTRW5ITVJ?
U-698-M M3XZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC4VW9KSzVyPUeuPFQ{OTVizszN NX63cJlQW0GQR1XS
KP-N-RT-BM-1 M3;ocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTdwOUOwNlkh|ryP NVP0[YNDW0GQR1XS
MS-1 M{Tv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTdwOU[wOFEh|ryP Mly0V2FPT0WU
SNU-C1 NEDlTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzLTWM2OD15Lkm4NVkzKM7:TR?= NXn1SG1wW0GQR1XS
SK-MM-2 NHrpZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnzTWM2OD16LkK2NFY2KM7:TR?= Ml;yV2FPT0WU
LAN-6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV30SXV[UUN3ME24MlMxODBzIN88US=> MXPTRW5ITVJ?
NEC8 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRThwM{C2PVEh|ryP MkDpV2FPT0WU
NCI-H1770 M3;t[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fHXmlEPTB;OD6zPFAxOiEQvF2= NVHXeW9iW0GQR1XS
D-336MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDSS4hsUUN3ME24MlQxOTF4IN88US=> M3u3bnNCVkeHUh?=
COLO-829 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PWcWlEPTB;OD60PFg4QSEQvF2= NFrSO2NUSU6JRWK=
LS-513 NEDXbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTMcnZKSzVyPUiuOVk2QTlizszN NWLCdVRsW0GQR1XS
YT MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrOTWM2OD16Lk[yOFI4KM7:TR?= MlLFV2FPT0WU
EW-24 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlixTWM2OD16Lke2OVQh|ryP MlnYV2FPT0WU
IST-SL1 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRThwOE[1OFMh|ryP M{jaT3NCVkeHUh?=
CA46 NYr3VZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm0T4RSUUN3ME24Mlk2ODl6IN88US=> MUjTRW5ITVJ?
NCI-H1838 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPrfpA5UUN3ME24Mlk5PjB{IN88US=> MVTTRW5ITVJ?
NCI-H719 NUD0ZW5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTrXItKSzVyPUmuNlUzPzlizszN MWTTRW5ITVJ?
HCE-T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTZUlVKSzVyPUmuN|A5PTFizszN MUnTRW5ITVJ?
A498 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;FZoRKSzVyPUmuN|YyOjRizszN MoH1V2FPT0WU
LB831-BLC NWHI[G5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrGbG5IUUN3ME25Mlc3PTJzIN88US=> NXrqd3ZSW0GQR1XS
SKM-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rL[GlEPTB;OT64OVk3OyEQvF2= NEPwXFNUSU6JRWK=
THP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu0V5k2UUN3ME25Mlk3QTF6IN88US=> M1ryWnNCVkeHUh?=
SHP-77 NVT2eoZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;FTWM2OD1zMD60NFch|ryP MVnTRW5ITVJ?
EW-3 NVHFelNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PxZ2lEPTB;MUCuOlI5QSEQvF2= NWjXelRZW0GQR1XS
KY821 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO1NJQzUUN3ME2xNE44PjNizszN MnGxV2FPT0WU
NCI-SNU-1 NEPBdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjZRYNKSzVyPUGxMlAzOTdizszN MmrJV2FPT0WU
HCC2218 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEntcI5KSzVyPUGxMlM6QDZizszN NYLhepdDW0GQR1XS
IM-9 NGrxW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjzTVJLUUN3ME2xNU42OTB4IN88US=> NUfXW2pKW0GQR1XS
NCI-H889 NVzzV5hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfy[41nUUN3ME2xNU42OzF|IN88US=> M3;ucHNCVkeHUh?=
HDLM-2 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHoTWM2OD1zMj60NVU6KM7:TR?= MnPxV2FPT0WU
LB2518-MEL NYntNJdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rydWlEPTB;MUKuOlgyPSEQvF2= NVnCSoVwW0GQR1XS
NCI-H23 NIHpbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLHTWM2OD1zMz6yOFI2KM7:TR?= MXfTRW5ITVJ?
NB17 NF\DeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF|LkS1O|kh|ryP NFXzTGZUSU6JRWK=
NCI-H322M NIPJ[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULQeHZzUUN3ME2xOE41ODZ6IN88US=> NI\KfGJUSU6JRWK=
SUP-T1 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXLTWM2OD1zND60NVMh|ryP MUXTRW5ITVJ?
ES3 NH\oPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTWTIgyUUN3ME2xOU4xPzB|IN88US=> NHPqNWRUSU6JRWK=
ES5 NH31PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjKXIxKSzVyPUG1MlA4QDdizszN M1jnN3NCVkeHUh?=
NCI-H1650 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF3LkS5O|kh|ryP MkDRV2FPT0WU
NCI-H226 M4noWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF3Lki3Olgh|ryP NHzaPY1USU6JRWK=
COR-L88 NGTxPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7STWM2OD1zNj6zNVQh|ryP M{LvXnNCVkeHUh?=
SCC-15 M12wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTnTWM2OD1zNj6zPFY6KM7:TR?= MX;TRW5ITVJ?
GOTO NHTZeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzITWM2OD1zNj60O|k{KM7:TR?= NHrISVNUSU6JRWK=
SIMA M{fUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi3SXRWUUN3ME2xOk41QDB{IN88US=> M3vxUnNCVkeHUh?=
NCI-H1299 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF5LkG1PVEh|ryP MnLsV2FPT0WU
NCI-H1581 NFH1VYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLLTWM2OD1zNz60NlE6KM7:TR?= M1\YUXNCVkeHUh?=
MHH-NB-11 NUjSNXljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\OPWlEPTB;MUeuPVY5OyEQvF2= NVnnOW1KW0GQR1XS
MFM-223 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHqfmpKSzVyPUG4MlA2OzhizszN M3rzcXNCVkeHUh?=
ES7 NXLyRo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGyTWM2OD1zOD61OFMyKM7:TR?= M1nlfXNCVkeHUh?=
JVM-3 NHH1UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nye2lEPTB;MUiuO|E4KM7:TR?= MmPMV2FPT0WU
RL M3fLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\HNm1KSzVyPUKwMlM5QCEQvF2= NIKzd|VUSU6JRWK=
EC-GI-10 NV70R|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL2[W1KSzVyPUKxMlIxPDFizszN NYHsbld7W0GQR1XS
LNCaP-Clone-FGC M13Xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHobWdOUUN3ME2yNU43PzZ6IN88US=> NVPFW|VNW0GQR1XS
IMR-5 M3jtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJzLki0PVQh|ryP NXXOfpY2W0GQR1XS
KP-N-YS MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3iVW1KSzVyPUKxMlg4PSEQvF2= MUTTRW5ITVJ?
Mo-T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXCdJVKSzVyPUKyMlIyQDVizszN NFHaVoVUSU6JRWK=
NCI-H128 NEX6SlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrwbGp1UUN3ME2yN{42QDV|IN88US=> MXfTRW5ITVJ?
RH-1 NIT2V5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrpNHNKSzVyPUKzMlc5PjZizszN M{XIbHNCVkeHUh?=
NCI-H2171 NYHTR3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPQcplLUUN3ME2yOE4zPDh3IN88US=> NGfwOXFUSU6JRWK=
RPMI-8866 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz2T5E4UUN3ME2yOk44PDJizszN NGSzVFhUSU6JRWK=
SK-N-FI NYjLblFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\sZ3JKSzVyPUK3MlM5OTFizszN MkjQV2FPT0WU
LOXIMVI NELCWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ5LkiwOVEh|ryP NGrTOXRUSU6JRWK=
P31-FUJ MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNzLkWzO|Qh|ryP NVT1V2F7W0GQR1XS
KMS-12-PE MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDWTWM2OD12OT61N|AzKM7:TR?= MUDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 3年-20℃
2年-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485は一種の有効的で、細胞浸透性 mTOR 活性剤で、オートファジー(autophagy)も有効に抑制します。

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021)は一種のGSK-3αとGSK-3β阻害剤で、IC50値が10 nM と6.7 nMに分かれます。

  • Dorsomorphin (Compound C, BML-275)

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183)は一種の有効的で、経口生物利用可能なAkt阻害剤で、Akt1、Akt2とAkt3に作用する時のKi値が0.08 nM、2 nMと2.6 nMそれぞれに分かれます。臨床2期。

  • Everolimus (RAD001)

    Everolimus (RAD001)は一種のmTOR阻害剤で、FKBP12に作用します。無細胞試験でIC50値は1.6-2.4 nMになります。

  • AZD8055

    AZD8055は一種の新たなATP競争性mTOR阻害剤で、MDA-MB-468細胞の中でIC50値は0.8 nMです。AZD8055はmTORに作用する選択性はPI3K亜型とATM/DNA-PKに作用する選択性より約1000倍が高くなります。臨床1期。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1は一種の有効なmTORC1/2阻害剤で、無細胞試験でIC50値が2 nM/10 nMになって、mTORに作用する選択性はPI3Kに作用する選択性より1000倍が高くなります。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は一種の特定なmTOR阻害剤で、無細胞試験でIC50値は1.76 μMです。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は一種の有効的で、選択性mTOR阻害剤で、無細胞試験でこのIC50値が1 nMです。INK 128 (MLN0128)はmTORに作用する効果はI型PI3K亜型に作用する効果より200倍以上が高くなります。ラパマイシン(Rapamycin)に比べて、INK 128 (MLN0128)は優先にmTORC1/2を抑制し、促侵入遺伝子( pro-invasion genes )に敏感です。臨床1期。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ